1 terminated. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
Follow CINJRegulatory: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery aldesleukin, ipilimumab, laboratory biomarker analysis - Recurrent Melanoma, Stage IIIA Melanoma | Phase 2 | Terminated | CINJRegulatory | 9 | 2014-11-26 | 2023-07-18 |
Melanoma (1)
CTLA-4 Antigen (1) · Interleukin-2 (1) · Ipilimumab (1) · aldesleukin (1)
United States (1)
Howard Kaufman (1)
P30CA072720 (1)